Ascendis Pharma announced the expiration of the regulatory waiting period for its collaboration agreement with Novo Nordisk, ...

With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...

Lead product MBX 2109 is a prodrug of parathyroid hormone (PTH), which is deficient in hypoparathyroidism, and a would rival to Ascendis ... 1/GIP drugs – like Novo Nordisk's semaglutide and ...

Shares of Novo Nordisk (CSE: NOVOb) continued their upward momentum on Tuesday, rising over 5%, following gains on Monday.

Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Bad news for Novo Nordisk (NVO 4.37%) Friday was good news for Eli Lilly (LLY 3.71%) and Viking Therapeutics (VKTX 0.17%), its two main rivals in the field of weight loss drugs. This morning ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...